Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 3
1999 1
2000 6
2001 18
2002 34
2003 34
2004 48
2005 60
2006 67
2007 71
2008 98
2009 125
2010 124
2011 152
2012 153
2013 152
2014 158
2015 132
2016 109
2017 101
2018 84
2019 61
2020 75
2021 84
2022 69
2023 88
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

1,883 results

Results by year

Filters applied: . Clear all
Page 1
[Olmesartan-associated Enteropathy].
Zou L, Wang Q, Li Y, Yang AM. Zou L, et al. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2021 Dec 30;43(6):986-990. doi: 10.3881/j.issn.1000-503X.13268. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2021. PMID: 34980342 Review. Chinese.
Olmesartan,an angiotensin receptor blocker,is a commonly used antihypertensive drug.Several case reports and cohort studies in recent years have described a severe gastrointestinal adverse event with chronic diarrhea,intestinal malabsorption,and weight loss after the admin …
Olmesartan,an angiotensin receptor blocker,is a commonly used antihypertensive drug.Several case reports and cohort studies in recent …
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Rakugi H, et al. Hypertens Res. 2022 May;45(5):824-833. doi: 10.1038/s41440-021-00819-7. Epub 2022 Jan 21. Hypertens Res. 2022. PMID: 35058583 Free PMC article. Clinical Trial.

Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitril/valsartan vs. olmesartan (P < 0.05 for all), were also observed. ...The safety and tolerability profiles of sacubitril/valsarta

…
Greater reductions in msSBP with sacubitril/valsartan 400 mg vs. olmesartan, as well as in msDBP and msPP with both doses of sacubitr …
Olmesartan-associated sprue-like enteropathy.
Briongos-Figuero LS, Cuevas-González J. Briongos-Figuero LS, et al. Lancet. 2023 Nov 4;402(10413):1660. doi: 10.1016/S0140-6736(23)02277-8. Lancet. 2023. PMID: 37925200 No abstract available.
Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study.
Kario K, Rakugi H, Yarimizu D, Morita Y, Eguchi S, Iekushi K. Kario K, et al. J Am Heart Assoc. 2023 Apr 18;12(8):e027612. doi: 10.1161/JAHA.122.027612. Epub 2023 Apr 7. J Am Heart Assoc. 2023. PMID: 37026551 Free PMC article. Clinical Trial.
Methods and Results Data from a randomized clinical trial comparing the BP-lowering effects of 8 weeks of treatment with sacubitril/valsartan (200 or 400 mg/d) and olmesartan (20 mg/d) in Japanese patients with mild-to-moderate hypertension were analyzed. ...Both sacubitri …
Methods and Results Data from a randomized clinical trial comparing the BP-lowering effects of 8 weeks of treatment with sacubitril/valsarta …
Olmesartan.
Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Al-Jallal AAM. Al-Majed AA, et al. Profiles Drug Subst Excip Relat Methodol. 2017;42:241-286. doi: 10.1016/bs.podrm.2017.02.005. Epub 2017 Mar 31. Profiles Drug Subst Excip Relat Methodol. 2017. PMID: 28431778
Olmesartan is an angiotensin receptor blockers with actions similar to those of losartan; it is used for the treatment of high blood pressure by relaxing blood vessels for this reason blood can flow more easily. It could be used alone or in combination with other antihyper …
Olmesartan is an angiotensin receptor blockers with actions similar to those of losartan; it is used for the treatment of high blood …
Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, Guo W. Williams B, et al. Hypertension. 2017 Mar;69(3):411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556. Epub 2017 Jan 16. Hypertension. 2017. PMID: 28093466 Clinical Trial.
Patients (n=454; mean age, 67.7 years; mean seated systolic blood pressure, 158.6 mm Hg; mean seated pulse pressure, 69.7 mm Hg) were randomized to receive once-daily sacubitril/valsartan 200 mg or olmesartan 20 mg, force titrated to double the initial doses after 4 weeks, …
Patients (n=454; mean age, 67.7 years; mean seated systolic blood pressure, 158.6 mm Hg; mean seated pulse pressure, 69.7 mm Hg) were random …
Olmesartan/amlodipine: a review of its use in the management of hypertension.
Kreutz R. Kreutz R. Vasc Health Risk Manag. 2011;7:183-92. doi: 10.2147/VHRM.S16852. Epub 2011 Mar 29. Vasc Health Risk Manag. 2011. PMID: 21490944 Free PMC article. Review.

Significantly greater reductions in seated diastolic BP were observed between baseline and after eight weeks of treatment with olmesartan/amlodipine, compared with equivalent doses of olmesartan or amolodipine monotherapy (P < 0.001), in the factorial Combination

…
Significantly greater reductions in seated diastolic BP were observed between baseline and after eight weeks of treatment with olmesartan …
Olmesartan-induced enteropathy.
Onteddu NK, Pulivarthi VSKK, Ginnavaram M, Kedika R. Onteddu NK, et al. BMJ Case Rep. 2018 Oct 2;2018:bcr2018224411. doi: 10.1136/bcr-2018-224411. BMJ Case Rep. 2018. PMID: 30279248 Free PMC article.
Olmesartan-induced enteropathy (OIE) typically presents with a constellation of signs and symptoms including chronic diarrhoea, weight loss and villous atrophy on biopsy. ...This report serves as an addition to existing literature and to increase the awareness of olmesa …
Olmesartan-induced enteropathy (OIE) typically presents with a constellation of signs and symptoms including chronic diarrhoea, weigh …
[Olmesartan therapy and enteropathy: About two cases and review of the literature].
Sadki A, Le Besnerais M, Héron F, Marie I. Sadki A, et al. Rev Med Interne. 2019 Feb;40(2):112-116. doi: 10.1016/j.revmed.2018.08.006. Epub 2018 Aug 31. Rev Med Interne. 2019. PMID: 30174111 Review. French.
INTRODUCTION: Olmesartan is an angiotensin II receptor blocker, used to treat arterial hypertension. Severe digestive manifestations have been associated with olmesartan, including sprue-like enteropathy and lymphocytic colitis. ...
INTRODUCTION: Olmesartan is an angiotensin II receptor blocker, used to treat arterial hypertension. Severe digestive manifestations …
Olmesartan-Induced Enteropathy.
Adike A, Corral J, Rybnicek D, Sussman D, Shah S, Quigley E. Adike A, et al. Methodist Debakey Cardiovasc J. 2016 Oct-Dec;12(4):230-232. doi: 10.14797/mdcj-12-4-230. Methodist Debakey Cardiovasc J. 2016. PMID: 28289500 Free PMC article.
Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are villous atrophy and increased intraepithelial lymphocytes. Clinical presentation of olmesartan-induced enteropathy includes diarrhea …
Olmesartan-induced enteropathy mimics celiac disease clinically and pathologically. As in celiac disease, the pathologic findings are …
1,883 results